Daclatasvir Dihydrochloride Intermediatus CAS 1007882-236 Puritas >98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. est primarium opificem Daclatasviri Dihydrochloridis Intermedii (CAS: 1007882-23-6) cum qualitate alta.Ruifu Chemical traditio terrarum, quantitatis competitive, parvae et quantitatis quantitatis in promptu est, praebere potest.Purchase Daclatasvir Dihydrochloride Intermedia,Please contact: alvin@ruifuchem.com
| Nomen chemicum | Di-tert-Butyl (2S,2'S)-2,2'-(4,4'-Biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-Pyrrolidinecarboxylate) |
| Synonyma | Daclatasvir Intermedias Ⅱ;Dacaltasvir medius 02;Daclatasvir T-Butyl Ester;Bis(2-Methyl-2-Propanyl) (2S,2'S)-2,2'-[4,4'-Biphenyldiylbis(1H-Imidazole-4,2-diyl)]di(1-Pyrrolidinecarboxylate);Di-tert-butyl 2,2′-([1,1′-Biphenyl]-4,4′-diylbis(1H-Imidazole-5,2-diyl))(2S,2S)-bis(Pyridineidine-1- Carboxylate);(2S,2'S)-2,2'-([1,1'-Biphenyl]-4,4'-diyldi-1H-Imidazole-5,2-diyl)bis-1' (1,1-Dimethylethyl) Ester;Daclatasvir impudicitia 4 |
| Stock Status | In Stock, Commercial Productio |
| CAS Number | 1007882-236 |
| Formulae hypotheticae | C40H51ClN8O6 |
| M. Pondus | 775.35 g/mol |
| Ferveret | 890.2±65.0℃ at 760 mmHg |
| Density | 1.220±0.06 g/cm3 |
| COA & MSDS | Praesto |
| Origin | Shanghai, China |
| Categoria | Intermedia Daclatasvir Dihydrochloride (CAS: 1009119-65-6) |
| Brand | Ruifu Chemical |
| Items | Specifications | Proventus |
| Aspectus | Lux Yellow ad Yellow pulverem | Lumen Yellow Pulvis |
| Damnum in Siccatio | <1.00% | 0.65% |
| Maximum Impuritas | <1.00% | 0.45% |
| Totalis immunditias | <2.00% | 1.24% |
| Puritas / Analysis Methodus | >98.0% (HPLC) | 98.76% |
| Infrared Imaginis | Congruunt Structure | Obsequitur |
| 1H NMR Imaginum | Congruunt Structure | Obsequitur |
| conclusio | Productum probatum est et cum datis specificationibus obsequitur | |
| Applicationem | Intermedia Daclatasvir Dihydrochloride (CAS: 1009119-65-6) | |
Sarcina:Fluorinated Utrem, aluminium ffoyle, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Continentem arcte clausam et in frigido, sicco et bene ventilato horreis a substantiis incompossibilibus repone.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Di-tert-Butyl (2S,2'S)-2,2'-(4,4'-Biphenyldiylbis(1H-imidazole-5,2-diyl))di(1-Pyrrolidine-carboxylate) (CAS: 1007882-23-6) est intermedia Daclatasvir Dihydrochloride (CAS: 1009119-65-6).
Daclatasvir (Daklinza) statum "prioritatis recensionis" consecutus est, cum Sorafenib coniunctus ad curationem genotypi III aegros adulti cum hepatitis chronicis C. Daklinza primum medicamentum, quod in curatione genotypi III hepatitis C virus efficax probatum est. infectio sine co-administratione cum interferone vel ribavirino.Interfezionis et Ribavirin duo medicamenta ab FDA probata sunt ad infectio virus hepatitis C curationis.Hepatitis C est morbus viralis qui inflammationem iecoris causare potest, consequens in diminutione hepatis vel defectus iecoris munus.Plerique cum hepatitis C infecti signa nulla habent donec damnum iecoris appareat, quod pluribus annis capere potest.Globally, genotypum III hepatitis C est secundum genotypum hepatitis C post genotypum 1 hepatitis C frequentissimum et unus e morborum genotypo refractorio censetur.Daklinza pan-genotypus NS5A est replicatio inhibitoris complexi, cum efficacia inhibitionis RNA replicationis et conventus viralis, effectus antiviralis duplicatus.Nam in studiis vitro Daklinza demonstratum est anti-viralem effectum habere contra genotypum 1~6 hepatitis C virus.Daklinza monitum comitatur est ut coniunctio amiodarone, Daklinza et Sofosbuvir graviter reducta cor rate causare possit.Daklinza tabula oralis est cum dosi suadeo 60 mg pro 1 temporibus/d, in conjunctione cum Sofosbuvir per totalem 12 septimanas.
Investigationes et progressus societatis: Bristol-Myers Squibb.
Litterae patentes: WO 2008021927A2 (9 Augusti 2007).
Tempus venalicium: 24 Iulii 2015 in Iunctus Civitas, nomen artis Daklinza recensetur.
Indicia: In compositione cum Sofosbuvir adhibita ad curationem genotypi 3 hepatitis chronici C (HCV) infectio.
Mechanismus agendi: HCV dapibus inhibitores nonstructurales 5A (NS5A).Motus adversa: dolores et lassitudines.
Formulae et specificationes: Tabulettae, 30 et 60 mg.
